10-Q: Azitra Reports Q3 2026 Results, Faces Funding Needs

Azitra, Inc. filed its Q3 2026 10-Q, detailing ongoing research and development efforts, significant operating losses, and a critical need for future financing to sustain operations.

Summary

• Azitra, Inc. reported its financial results for the quarter and nine months ended September 30, 2026.
• The company experienced a net loss of $2,949,779 for the three months ended September 30, 2026, and $10,224,679 for the nine months ended September 30, 2026.
• Total operating expenses for the three months were $2,905,458, an increase of 5% from the prior year, and $10,258,550 for the nine months, an increase of 17%.
• As of September 30, 2026, the company had cash and cash equivalents of $3,750,710 and total assets of $5,973,593.
• The company has an accumulated deficit of $78,745,875.
• Azitra continues to advance its product candidates, including ATR-COSF, ATR-04, and ATR-01, with ongoing clinical and IND-enabling studies.
• The company regained compliance with NYSE American continued listing standards in August 2026 but notes its stockholders' equity remains below a key threshold.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to its financial condition and need for future funding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued operating losses, substantial accumulated deficit, and ongoing need for significant additional funding, despite some positive developments in clinical trials and regained listing compliance.

Positives

• Regained compliance with NYSE American continued listing standards on August 19, 2026.
• The FDA granted Fast Track designation for the ATR-04 program in September 2024.
• The Safety Review Committee recommended proceeding to dose patients in Cohort 2 of the ATR-04 Phase 1/2 clinical trial.
• Initial clinical safety results for ATR-12 were reported in the first half of 2025, leading to an improved formulation and next-generation candidates.
• The company has a diverse pipeline of product candidates for precision dermatology and cosmetic ingredients.
• Significant progress in IND-enabling studies for ATR-01 and advancement of ATR-COSF towards clinical trials.

Negatives

• Net loss of $2,949,779 for Q3 2026 and $10,224,679 for the first nine months of 2026.
• Accumulated deficit of $78,745,875 as of September 30, 2026.
• Substantial doubt about the company's ability to continue as a going concern.
• Stockholders' equity of $4.4 million as of September 30, 2026, is below the $6.0 million minimum required by NYSE American Section 1003(a)(iii).
• Enrollment in the ATR-12 Phase 1b clinical trial was paused in June 2026 to conserve capital.
• Increased operating expenses, with a 5% rise in G&A and a 9% rise in R&D for Q3 2026 compared to the prior year.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to its financial condition and need for future funding.
• Future noncompliance with NYSE American listing standards could result in delisting, impacting liquidity, market price, and ability to raise capital.
• The exercise of outstanding warrants and options, and future equity issuances, could result in substantial dilution to existing stockholders.
• The company is dependent on contract research organizations (CROs) and contract manufacturing organizations (CMOs), and any interruption in their operations could adversely affect development programs.
• Product candidates require FDA or other regulatory approvals, and there is no assurance that these approvals will be obtained or maintained.
• The company's development programs are subject to the risks of failure inherent in the pharmaceutical industry, including clinical trial failures and competition.

Future Outlook

The company expects its general and administrative expenses to increase modestly due to personnel and facility costs, as well as increased costs associated with being a public company. Research and development expenses are expected to increase significantly due to planned clinical trial activity, continued product candidate development, and personnel hires. Future other income is expected to be consistent with prior periods. The company anticipates needing significant additional funds to complete product development and fund future losses, and plans to raise funds through equity and/or debt financing.

Management Comments

• Management expects that our general and administrative expenses will incur a modest increase in the future as a result of personnel costs and facility operating costs. We also expect an increase in costs associated with being a public company, including costs related to accounting, audit, legal, consulting fees, regulatory and tax-related services associated with maintaining compliance with applicable NYSE American and SEC requirements, additional director and officer insurance costs, and investor and public relations costs.
• We expect our research and development expenses to significantly increase in the future due primarily to our planned clinical trial activity and continued development of product candidates, the research and development of cosmetic ingredients for our consumer-oriented products, and planned increases in personnel costs due to additional resource hires.
• Management has determined there is substantial doubt about our ability to continue as a going concern based on our lack of revenue from commercial operations, significant losses, and the need to raise additional capital to support ongoing operations.

Industry Context

StockSavvy.ai notes that Azitra operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on synthetic biology for precision dermatology. The company's reliance on ongoing R&D and clinical trials, coupled with its pre-commercialization status, aligns with typical industry challenges. The need for substantial future financing is a common theme among early-stage biotechs aiming to bring novel therapies to market.

Comparison to Industry Standards

• The company's net loss of $10.2 million for the first nine months of 2026 and accumulated deficit of $78.7 million are substantial for a pre-commercial company, but not uncommon in the biotech sector where significant investment is required for drug development.
• The company's cash burn rate of approximately $8.7 million for the first nine months of 2026 is a critical factor. Many early-stage biotechs face similar cash burn rates, necessitating frequent capital raises.
• The company's strategy of developing both therapeutic candidates and cosmetic ingredients is a diversification approach seen in some biotech firms to generate earlier revenue streams or leverage platform technologies across different markets.
• The company's reliance on equity financing (IPO, follow-on offerings, ELOC) is standard for the industry, reflecting the difficulty in securing debt financing for pre-revenue companies.

Legal Proceedings

• The company is subject to legal proceedings or claims which arise in the ordinary course of its business, but management believes the final disposition will not have a material adverse effect.

Related Party Transactions

• Purchasers in the Series A Offering included the Company's Chief Executive Officer, a consultant to the Company, and a holder of more than 5% of the Company's outstanding common stock as of the date of the Series A Purchase Agreement.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and warrant/option exercises.
• Shareholders are exposed to the risk of delisting if the company fails to maintain NYSE American listing standards.
• Creditors and suppliers may face uncertainty regarding the company's ability to continue as a going concern and meet its financial obligations.
• Employees may face uncertainty regarding job security due to the company's financial situation and need for future funding.

Next Steps

• Continue IND-enabling studies for ATR-01.
• Conduct a cosmetic study for ATR-COSF in Q4 2026.
• Potentially resume ATR-12 development with improved formulations.
• Continue to seek additional equity and/or debt financing.
• Explore strategic partnerships and licensing opportunities.
• Continue to monitor and ensure compliance with NYSE American listing standards.

Key Dates

Recommendation

The company shows promise in its R&D pipeline and has regained listing compliance, but the significant operating losses, substantial accumulated deficit, and critical need for future financing create considerable risk. While there are positive developments, the going concern uncertainty and potential for dilution warrant a cautious 'hold' stance until a clearer path to profitability or sustainable funding is established.

Keywords

synthetic biology, dermatology, live biotherapeutic products, engineered proteins, clinical trials, drug development, biotechnology, regenerative medicine